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Abstract 
 
The characterization of particulate matter, especially protein aggregates, in the sub-
visible and visible size range has become an area of focus in the biopharmaceutical 
industry.  This heightened focus is due, in part, to increasing concern around particles 
causing immunogenicity, and increased queries from regulatory bodies. There has been 
extensive research in this area, with many recent publications on related methodologies, 
mechanisms and influencing factors.  Two areas of interest are the characterization of 
these particles using material sparing approaches and the effect of the presence of 
silicone oil particles on protein solutions. 
 
With the focus on high concentration drug products (≥50 mg/mL), and the drive toward 
conserving drug product by producing fewer batches, there is a real need for 
characterization techniques that require less sample.  In addition, there is significant 
interest by the regulatory agencies in obtaining information on particulate matter in 
biologic drug products over a broad range of sizes.  Queries are being generated by the 
FDA and other regulatory bodies, asking for particle count and any additional 
compositional information.  They are requiring the pharmaceutical industry to have a 
deeper understanding of the formation of protein particles as well as methods for 
monitoring a broad range of sizes, over the shelf life of the product. 
 
The propensity exists for increased protein aggregation at higher concentrations, yet 
companies are generating less sample material for testing during development.  The focus 
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of this dissertation was to develop approaches for characterizing protein aggregation 
(particulates) using minimal sample amounts.  To develop validatable methods for 
ongoing drug product monitoring as well as more novel approaches to better understand 
the nature of particulate matter present in biologic drug products.  Silicone oil is present 
in many drug product contact surfaces and was chosen for further study on the effect of 
protein aggregation.  The methods developed during this research were utilized to 
characterize protein and/or silicone oil particles, and to provide differentiation between 
protein and non-protein particles. 
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Chapter 1.  Issues with Particles in Biologic Samples 
1.1  Introduction 
The number of biopharmaceutical products being submitted for FDA approval has 
rapidly increased over the last several years.  In 2009, the FDA granted 18 full approvals 
for biopharmaceutical products [1].  This was the highest number of new product 
approvals since 2005.  Proteins used in these biologics can be susceptible to self-
association which can lead to aggregation.  This is especially true for products being 
formulated at higher concentrations (usually >50 mg/mL).  These aggregates can range in 
size from a few monomer units to hundreds of microns.   
 
Protein aggregation has been an area of study for many years.  Aggregates form as a 
result of association of protein molecules.  This occurs from some instability of the 
protein in its environment.  These instabilities have been well studied and can be caused 
by chemical and/or physical means [2, 3].  A protein aggregate has been described as a 
species of higher molecular weight (a multimer) that can be associated by covalent bonds 
or non-covalent interactions [4].  Non-covalent aggregates are formed by weak forces 
such as Van der Waals interactions, hydrogen bonding, hydrophobic and electrostatic 
interactions.  Covalent aggregates can be formed from disulfide linkages through free 
thiol groups or non-disulfide cross linking pathways such as dityrosine formation.  Self 
association of proteins can occur with changes in formulation parameters such as pH, 
ionic strength, buffer species or from high protein concentration (macromolecular 
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crowding).  Aggregation can also be affected by temperature, mechanical stress (shaking, 
pumping, stirring) and interactions with foreign particles from contact surfaces (causing 
nucleation). 
 
There are several models for protein aggregate formation, including: 
1. Lumry-Eyring two state model, where 
Native protein  reversible conformational change (aggregation prone state)  
assembly to an irreversible aggregated state. 
2.  Nucleation-propagation polymerization mechanism, where the nucleus can be 
from altered monomer or multimer species. 
3. Heterogeneous nucleation, where aggregation is induced by micro/nanoparticles 
of foreign matter. 
 
There are two main types of protein instabilities, chemical and physical.  Chemical 
instabilities can lead to new chemical entities, whereas physical instabilities do not cause 
a change in chemical composition. 
 
Chemical instability 
Deamidation is considered one of the most common chemical degradation pathways, 
involving the hydrolysis of Asn and Gln side chain amides.  In peptides, the main factors 
that affect deamidation rates are the protein primary sequence, temperature and pH [5, 6].  
In folded proteins, the secondary and tertiary structure influences the rate of deamidation, 
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most often slowing the degradation process but in some cases accelerating the reaction [7, 
8].  Hydrolysis can occur at the peptide backbone.  Asp hydrolysis (also known as 
proteolysis), involves intramolecular cyclization and the rate is pH dependent and can be 
caused by buffer catalysis.  Hydrolysis can occur, even when Asp is not present.  Some 
IgG1’s have been shown to undergo hydrolysis in the hinge region [9].  For some mAbs, 
this reaction can be metal catalyzed.  There are other chemical reactions that can occur 
with proteins such as racemization, B-elimination, pGlu formation, and glycation (a 
Maillard reaction).  Another primary chemical degradation pathway is oxidation, which 
can affect any protein containing His, Met, Cys, Tyr, and Trp amino acids.  These amino 
acids can react with reactive oxygen species (free radicals that can be generated from a 
variety of sources) at any time during the development of a protein drug product.  The 
reaction is nearly pH independent.  A common residue to track for potential oxidation is 
Met.  It is very sensitive to oxidation, even in the presence of molecular oxygen (as long 
as the residue is accessible by the solvent it is present in).  Other oxidation reactions 
include metal-catalyzed oxidation, Trp oxidation, photo-oxidation, and cysteine 
oxidation.  Photolytic degradation can occur from light exposure leading to photo-
oxidation of side chains of amino acids such as Met, Tyr, Trp, His, Cys, and Phe and has 
been shown to induce protein aggregation [4]. 
 
Physical instability 
Denaturation is a common term for physical degradation of a protein, which involves a 
change in the three dimensional structure (such as unfolding).  Denaturation, however, 
can involve changes to the secondary or tertiary structure.  Thermal denaturation is a 
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common mechanism of instability, usually caused by exposing the protein to elevated 
temperatures causing partial or full unfolding.  The unfolded molecules will tend to 
associate forming aggregates.  Other forms of denaturation include cold denaturation, 
chemical and pressure-induced denaturation.  Denaturation can also occur with exposure 
to a mechanical stress as described earlier. 
 
All of the instabilities reviewed (both chemical and physical) can lead to protein states 
that are amenable to aggregation.  An aggregate involves the association of protein 
molecules, which can come from covalent or non-covalent interactions, and vary greatly 
in the degree of reversibility.  Small aggregates are often soluble.  As these aggregates 
grow and continue associating, the resulting complexes can become large enough to 
detect visibly and often transform into insoluble particulates.  These entities are 
considered non-reversible.  One exception would be proteins that are salted-out, where 
the particles are insoluble, but retain activity and native-like structure.  The formation of 
these particles is reversible upon dilution.  The characterization of particulates is of great 
interest to the pharmaceutical industry and will be the topic of much of the research 
described in this dissertation. 
 
Therapeutic protein aggregates have been linked to issues such as loss of efficacy and 
immunogenicity.   Immunogenicity can be considered the ability of a material to induce 
an immune response in the body.  This can occur with the first introduction of the drug or 
through repeated administration.  For proteins that are human homologues (human-like), 
aggregation is the primary factor inducing immunogenicity [10].  It is this immunogenic 
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effect of protein products that is of great concern to the regulatory agencies and the 
pharmaceutical industry.  A recent CMC Strategy Forum meeting was held to discuss 
analysis and immunogenic potential of protein aggregates and particles.  Barry Cherney 
(DTP, CDER, FDA) was present and discussed arguments that have been made regarding 
the lack of direct evidence relating sub-visible protein aggregates to increased 
immunogenicity.  Arguments include that fact that the amount of protein in these 
particles is too small to induce a response [11].  Cherney was clear in stating that the 
level required for a particular product to induce a response is not known, especially when 
repeated dosing is involved.  The lack of data or knowledge does not eliminate the risk 
but creates unknown and uncontrolled risk.  He stated that since there is no clear evidence 
that sub-visible particles are not critical, the type and amount of these particles should be 
considered a critical quality attribute (CQA) and must be monitored and controlled 
appropriately.  It was clear from these discussions that measuring particulate matter 
during development and post approval is necessary and can be used to establish a direct 
link to clinical outcomes. 
 
1.2  Sub-visible Particles 
Compendial methods are in place to monitor sub-visible particle abundance in 
parenterals, such as the United States Pharmacopeia ( USP<788>).  The European and 
Japanese Pharmacopeia are harmonized with the USP.  These methods utilize light 
obscuration as the method for detecting and counting sub-visible particles.  These 
methods state that particle counts at 10 µm and greater and 25 µm and greater be 
monitored.  As discussed previously, there is a need to detect smaller particles when 
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dealing with biologic products.  The instruments can, depending on the sensor used, 
detect particles from approximately 1.5 to 400 µm.  The methods do however, require a 
large sample volume for analysis (approximately 25 mL).  The sample can be diluted if 
needed, but this is not ideal for protein solutions, where reversible aggregates can be 
affected. 
 
An alternative to light obscuration particle counting in the compendia, is an optical 
microscopy technique where the test solution is filtered onto a membrane and particulates 
are counted.  This technique is also optimized for detecting the presence of extrinsic or 
foreign particulate matter.  It has many limitations when analyzing for protein particles, 
including lack of contrast between protein particles and the membrane surface as well as 
amorphous protein particles embedding into the filter and never being detected.   
 
Another limitation to light obscuration is the lack of sensitivity to transparent particles.  
A technique based on micro-flow imaging (also known as flow microscopy) is gaining 
popularity as a means of counting sub-visible protein particles.  Instruments such as the 
Brightwell Micro-flow Imaging system and the FlowCam are gaining popularity for 
characterization of biologic products.  The technique is based on dynamic imaging of a 
sample as it flows past a high speed camera.  Images are obtained and can be analyzed for 
particle concentration as well as morphological features.  A study was performed by 
Glaxo Smith Kline comparing the ability of several techniques to detect protein 
aggregates versus a flow microscopy instrument [12].   Several protein formulations were 
subjected to freeze-thaw stress and monitored by flow microscopy, SEC (for % soluble 
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aggregate), icIEF (% main peak) and light obscuration.  For each formulation, a control 
sample and stressed sample were compared.  The only technique able to detect a 
difference in aggregate level was flow microscopy, where each formulation exhibited a 2-
10 fold increase in sub-visible particles.  Since micro-flow imaging was useful in 
detecting changes in aggregate levels, the team was able to look at the effect of excipients 
as stabilizers that prevent aggregate formation, such as Polysorbate 80.  Micro-flow 
imaging does show promise as a technique for monitoring sub-visible particles in protein 
solutions, but limitations still exist with the technology. 
 
The compendial methods were developed for monitoring the presence of extrinsic or 
foreign particulate matter in small molecule parenterals.  These methods have some 
critical limitations when analyzing biologic drug products for the presence of sub-visible 
aggregates.  Proteinaceous particles are amorphous, flexible and can vary greatly in 
morphology.  They can be very close in refractive index to the matrix they are found in, 
making them virtually transparent.  These optical and physical properties make them very 
challenging to detect using traditional sub-visible analysis approaches.  In addition to the 
limitations due to the properties of protein particles, many times there is very little 
material available during the biologic drug development process.  It is important to 
characterize the drug product throughout the development process.  There have been 
studies showing that in some formulations, as the number of subvisible particles grow, 
larger aggregates form eventually leading to the formation of visible particulates in the 
product [11]. 
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1.3  Visible Particles 
Visible particles are usually described as particles >100 µm in size.  At this size, the 
probability of detecting the particle is approximately 40%, and becomes greater than 95% 
for particles greater than or equal to 200 µm [13].  There are two primary methods for 
visible particle inspection- manual human inspection and automated inspection using a 
system such as the Eisai.  These methods are excellent at detecting defects and foreign 
particulate matter but may not be as sensitive to transparent protein particles, especially 
under specified inspection conditions as described in USP Gen Chapter 1.  Some of this 
limitation can be overcome with human inspection through proper training.  There is also 
a concern that the motion used in automated inspection systems could induce aggregation 
in sensitive products.  Some protein particles are very thin and transparent, creating a 
challenge for most inspection processes.  As such, the use of dyes to enhance contrast 
may provide a solution to the detection of these types of particles. 
  
In addition to detecting particles, it is becoming imperative that the composition be 
determined.  Particle counts are a critical quality attribute, and identification of the 
particles is becoming a more frequently discussed issue.  Cherney stated in the CMC 
forum meeting, techniques should be used to characterize the nature of particles detected 
[11].  This concept was further enforced in a recent publication by Wim Jiskoot et al. 
reviewing protein delivery systems.  The paper stated that the industry is in urgent need 
of methods that are capable of discriminating between particles, whether they be protein 
related or matrix related [14].  The identification of particulate matter must be considered 
one of the necessary analytical methods used to monitor the physical stability of a 
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biologic.  This dissertation provides modifications of current techniques and alternative 
methods to enhance detection and characterization of protein particles in the sub-visible 
and visible size range. 
 
1.4  Silicone Oil 
Although proteinaceous particles are an important topic for discussion, the presence of 
foreign particulates must be considered when characterizing biologic solutions.  A very 
common extrinsic particle found in biologic drug products is silicone oil.  Silicone oil is a 
common additive found in syringe barrels, certain stoppers, and inner surfaces of certain 
tubings and glass vials.  In prefilled syringe devices, silicone oil is applied to the inner 
barrel to decrease the glide force, making self injections easier for the patient.  Depending 
on the type of syringe, staked-in needle versus Luer lock, different processes of applying 
the silicone oil are used.  For syringes with a Luer lock tip, the oil is sprayed on, rinsed 
and can be baked.  Syringes with a staked in needle have the oil sprayed on, but due to 
the process of applying the needle, these syringes cannot be baked.  In general, the 
process of baking the coating, helps it adhere and results in less oil leaching into the 
product.  In many instances, the oil that has leached is emulsified and results in small 
spherical droplets in the drug product solution.  There have been studies suggesting that 
silicone oil can induce protein aggregation, but many recent studies have demonstrated 
that silicone oil did not cause any aggregate formation [15, 16].  The stability of 
lyophilized Albinterferon Alfa-2b was monitored with and without silicone oil (post 
reconstitution) for 3 weeks at 25ºC [17].  Several levels of silicone oil were spiked into 
the samples.  Over this time, silicone oil had no effect on the physical stability of the 
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material as determined by monitoring sub-visible particles by micro-flow imaging (the 
Brightwell).  Protein secondary and tertiary structure was not affected, as determined by 
FTIR and CD spectroscopy.  The authors noted that the formulation contained 
polysorbate 80, which may have protected the protein from silicone oil induced 
aggregation.  This study demonstrates the type of characterization that should be 
performed when screening formulations for the effect of the presence of silicone oil.  The 
authors state that greater than 98% of all particles were in the 1-10 µm size range.  In 
addition, increased particle counts were observed with increased silicone oil levels.  As 
mentioned previously, using the techniques outlined above, there was no easy way to 
determine if the increased counts were due to just neat silicone oil, or oil and protein 
interactions (such as protein coating the oil droplets).  If the oil droplet morphology 
remained fairly equant, the analytical techniques used would not be able to detect any 
interaction with protein. 
 
Another important factor to consider is the resolution of the images at small particle sizes 
(<10 µm).  The resolution with current micro-flow imaging techniques is moderate.  It is 
well known in the field of microscopy and image analysis that current imaging 
capabilities allow for resolution to approximately 5 µm.  This limit also applies to micro-
flow instruments, where the smallest object resolved is approximately 5 µm, and even 
more resolving power would be needed to perform any high level description of the 
particle [18].  Most particles will appear somewhat spherical at very small sizes, and it 
may be very difficult to distinguish a globular protein aggregate from an oil droplet, as 
shown in the gallery of images for a silicone oil sample and a sample of bovine serum 
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albumin (Figure 1.1).  It is difficult to differentiate particle types until particles reach 
approximately 10 µm or greater. 
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Figure 1.1.  The top set of images are silicone oil droplets, covering a range of particle 
sizes from 2-25 µm, obtained using a Brightwell MFI DPA4200.  The bottom set of 
images are a BSA sample, covering the same size range of particles, 2-25 µm.  Sizes are 
based on an equivalent circular diameter (ECD). 
 
Particles 2 to 5 µm (equivalent circular diameter)
Particles 5 to 8 µm (equivalent circular diameter)
Particles 8 to 10 µm (equivalent circular diameter)
Particles 10 to 25 µm (equivalent circular diameter)
 
 
 
Particles 2 to 5 µm (equivalent circular diameter)
Particles 5 to 8 µm (equivalent circular diameter)
Particles 8 to 10 µm (equivalent circular diameter)
Particles 10 to 25 µm (equivalent circular diameter)
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There have been several recent papers recommending the use of digital filters to remove 
particle counts when it is known that silicone oil is present in the sample.  As shown 
above, with such poor resolution it is dangerous to exclude any particles from the total 
count.  A recent study from Novartis showed application where it might be acceptable to 
digitally filter particles thought to be silicone oil [16].  A total of nine individual optical 
parameters were evaluated using images of solutions containing IgG-A and IgG-B 
protein particles along with silicone oil droplets.  There was significant overlap between 
these values in the 2-15 µm size range.   It was determined that no one parameter could 
provide adequate discrimination between protein particles and silicone oil droplets.  This 
would lead to high levels of error in classifying the particles.  Next, four optical 
parameters, along with cut-off values, were applied to analyze the same images.  The 
optical parameters were circularity (how circular a particle is), aspect ratio (the ratio of 
length to width of a particle), object intensity STD (standard deviation in the intensity 
value for the particle image) and object intensity MAX (the maximum value for the 
particle image).  This approach resulted in much better discrimination, especially above a 
particle size of approximately 5 µm.  Another advantage to this approach is the ability to 
fine tune the optical parameters and cut-off values to accommodate protein particles with 
different optical properties.  Although this approach does provide an interesting solution 
to discriminating silicone oil droplets, thus allowing for digitally excluding them, some 
knowledge of the particles present in solution must be obtained initially.  Also, this 
approach cannot determine if the silicone oil particles are associated with protein, 
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especially if the overall morphology remains fairly spherical.  This is important because 
even non-protein particles coated in protein can be highly immunogenic [11]. 
 
1.5  Outline of the Dissertation 
This dissertation provides approaches to aid in the characterization of sub-visible and 
visible protein particles, using a minimal amount of test material.  As discussed in the 
introduction, pharmaceutical companies are being asked to provide more detailed 
information on the abundance and type of particles present in biologic drug products.  
Chapter 2 provides details on the development and qualification of a procedure for using 
light obscuration, as described in USP <788>, but with much less sample volume, and the 
ability to monitor particles down to 2 µm in size.  In addition, the Brightwell micro-flow 
imaging system was compared to the light obscuration technique, focusing on possible 
causes for the discrepancy in particle counts consistently obtained when comparing these 
techniques.  Chapter 3 describes the use of a visible protein specific dye to be used in 
conjunction with optical microscopy.  As discussed previously, protein aggregates can be 
very difficult to detect by optical microscopy, even with optimized lighting conditions.  
Also, protein particles can be difficult to impossible to detect when filtered onto a 
membrane for characterization.  A dye can enhance the contrast between a protein 
particle and its matrix or a filter membrane.   This allows for visualization by microscopy 
as well as the ability to apply image analysis techniques to obtain both qualitative and 
quantitative information about the aggregates.  With the use of microscopy, both visible 
and sub-visible particles can be detected, down to approximately 1-2 µm.  Lastly, 
Chapter 4 describes an investigation of silicone oil droplets in the presence of protein 
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solutions/aggregates.  The possibility of protein coating silicone oil particles was probed.  
By using a fluorescent dye, silicone oil droplets associated with protein were detectable.  
This work could prove useful as a technique for understanding when silicone oil droplets 
can or cannot be ignored. 
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Chapter 2.  Particle Size and Count Methods 
 
2.1  Development and Validation of a Low Volume Light Obscuration Method, 
with Detection Below 10 µm 
2.1.1  Introduction 
Light obscuration testing for the quantitation of sub-visible particle counts is an 
established technique and cited in the compendia (eg;  USP, EP, JP).  These compendia 
are harmonized on the testing procedures; therefore USP<788> was cited when referring 
to compendial requirements.  The compendial method requires a large amount of test 
solution per sample analyzed (approximately 25 mL for a single analysis) [19].  During 
the development of a biologic, it would be of great benefit to monitor sub-visible particle 
counts but the amounts of solution required per the USP would be prohibitive.  It was 
desired to develop a method that would provide sub-visible particle count results using 
significantly less test volume. 
 
In addition to minimizing sample requirements, it was desired to monitor the particle 
counts below the compendial limit of 10 µm.  There is much discussion around the need 
to begin monitoring particle counts less than 10 µm.  In very recent years, the FDA has 
been asking pharmaceutical companies to provide additional particle count information 
for particles 1-2 µm and greater, in part due to the increased publications discussing the 
role of sub-10 µm protein particles in inducing immunogenicity [20]. 
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The HIAC light obscuration instrument is commonly used for USP<788> testing.  This 
type of method development is occurring within the pharmaceutical industry and will aid 
in our understanding of protein particle formation [21].This instrument can be modified 
to monitor particles down to approximately 2 µm.  It can also be equipped with a smaller 
gauge aspirator, allowing for lower volumes to be tested.  A study was performed to 
develop a HIAC method that would require minimal sample volume while analyzing 
particles in the 1.5-10 µm range as well as the 10-150 µm size range.   
 
2.1.2  Materials and Methods 
For this study, a HIAC/Royco Pacific Scientific Liquid Particle Counting System (model 
9703) was used for all light obscuration results.  A 10 mL aspirator was used with the 
instrument to allow for reduced test volumes.  A HRLD 150 sensor was installed in the 
instrument.  This sensor has a lower limit of detection of approximately 1 µm and an 
upper limit of 150 µm, allowing for monitoring particle counts down to 1.5 um.  A flow 
rate of 25 mL/min was used for all studies.  Particle count data were acquired using 
PharmSpec 2.0 software. 
 
Samples were handled under clean conditions, in a lab containing HEPA filtered air.  All 
test solutions were handled in a laminar air flow hood.  The conditions for testing meet 
suggested environmental conditions as described in USP<788>.  In addition, any 
glassware used during the study was pre-rinsed using particle free water, and stored in the 
laminar flow hood.  Any sample dilution, as well as instrument rinsing was performed 
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using MilliQ water (0.2 µm filtered).  A set of latex microsphere standards (NIST 
traceable) were used for this work, as describe in Table 2.1.  These standards contained 
monomodal size distributions at the nominal sizes stated.  In addition, bovine serum 
albumin (Sigma #A4503) was used in a robustness study. 
 
Table 2.1.  Latex particle standard information 
Item Vendor Catalog # 
Particle Count Standard- 2 um Thermo Fisher CC2-PK 
Particle Count Standard- 15 um Thermo Fisher CC15-PK 
Particle standard-5 um Thermo Fisher 9005 
Particle standard-15 um Thermo Fisher 9015 
 
2.1.2.1  Experimental Design 
The HIAC instrument used was calibrated by the vendor, on a 6 month schedule.  The 
calibration was extended over the complete size range, from 1 µm to 100 µm.  In 
addition, flow rate and aspiration volume accuracy were also qualified by the vendor 
before any experimentation.  A daily system suitability test was also performed, ensuring 
that the instrument particle counts met the certified value for the 15 µm particle standard. 
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2.1.2.2   Test Parameters 
Accuracy 
Count accuracy was determined using 15 µm and 2 µm certified count standards, neat.  
Both 0.5 mL and 1 mL injections were evaluated.  Four injections and six injections were 
evaluated per test volume, with the first injection discarded in all cases.  This is necessary 
since the first injection can have aberrant count values due to mixing of sample and rinse 
solution in the instrument.  The average cumulative counts per sample were recorded, and 
compared to the certified values available from the vendor. 
 
Linearity 
For this study, the 2 µm, 5 µm and 15 µm count standards were used.  A series of 
dilutions were created as shown in Table 2.2.  Each dilution was evaluated at a set of 
injection volumes including 0.5 mL, 1 mL, and 5 mL (5 mL being the volume described 
in USP<788>, and used for comparison to lower volumes tested).  The average 
cumulative counts per sample were recorded.  For the 2 µm standard, the cumulative 
counts at 1.5 µm were used.  For the 5 µm standard, the cumulative counts at the 2.5 µm 
size were used.  For the 15 µm standard, the cumulative counts at 10 µm were used.  It 
was critical that the counts at a size bin below the nominal standard size was used, since 
the particles comprise a normal distribution around the nominal particle size and all 
particles contributing to that distribution must be accounted for. 
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Table 2.2.  Dilution scheme for linearity test sample preparation. 
 
 Dilution 1 Dilution 2 Dilution 3 Dilution 4 Dilution 5 
Dilution conc 
(p/mL) 
1000 
 
500 
 
200 
 
100 
 
25 
 
Standard (mL) 
25 mL 
stock 35 mL D1 30 mL D2 35 mL D3 10 mL D4 
Water (mL) 50 35 45 35 30 
Total vol (mL) 75 70 75 70 40 
 
 
Precision 
The precision of a measurement is a critical parameter to evaluate.  Knowing the 
precision of a measurement aids in determining if two results are truly different.  Two 
vials of a standard particle suspension (22 mL each) were combined.  To this, 88 mL 
water was added for a total volume of 132 mL at 1000 particles/mL.  The suspension was 
analyzed at 5 mL, 1 mL and 0.5 mL injection volumes over 3 days (again, the first 
injection will be discarded for all runs).  A second sample was analyzed, diluted to the 
lower limit of detection to determine precision at low particle concentration.  The study 
design is shown in Table 2.3.  All conditions were compared to the variability obtained 
with the 5 mL injection volume since this is the compendial method parameter. 
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Table 2.3.  Design of study to determine the precision of the particle count 
measurements. 
 
Injection Volume 
(mL) No. Injections No. Replicates No. Days 
Total 
Volume 
(mL) 
5 4 1 3 60 
1 4 3 3 36 
0.5 4 3 3 18 
 
 
Specificity 
A study was conducted to look at the specificity of the particle count value when two 
particle size standards with significantly different concentrations were present in a single 
sample.  Two mixtures were created as shown in Table 2.4.  Both 5 mL and 1 mL 
injection volumes were evaluated versus expected concentration values. 
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Table 2.4.  Two stock solutions were prepared to evaluate the specificity of the particle 
count measurement. 
Stock #1 
Standard 
Standard vol. 
(mL) 
No. 
Particles Final conc. after adding 50 mL water 
2 µm 5 15,000 200 (particles/mL) 
15 µm 20 60,000 800 (particles/mL) 
 
Stock #2 
Standard 
Standard vol. 
(mL) 
No. 
Particles Final conc. after adding 50 mL water 
15 µm 5 15,000 200 (particles/mL) 
2 µm 20 60,000 800 (particles/mL) 
 
 
Robustness Studies 
Samples were tested for appropriate time and mode of degassing.  Samples were 
degassed by allowing to sit at ambient conditions for a specified period of time (0, 2, 5, 
10, 15, 20 and 30 minutes), or sonicated using a sonic bath for 30 or 60 seconds 
(additional time could be too aggressive for protein solutions, and could cause 
aggregation).  A last method of degassing was to place the sample under vacuum in a bell 
jar.  Samples were tested after 30 seconds, 2, 10, 20 and 30 minutes under vacuum. 
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Samples included 2 platform formulation buffers (Form A and Form B), particle free 
water and Form B with 10 mg/mL BSA added.  Form A buffer contained 10 mM 
potassium phosphate, pH 7.4 and Form B buffer contained 10 mM histidine, pH 6.0.  
Samples were mixed by vigorous manual shaking (inverting the vials) 30 times. 
 
2.1.3  Results 
2.1.3.1  Accuracy 
The count accuracy was tested using two standards, with different nominal diameters.  
All standards had a certified particle concentration of 3000 particles/mL ± 10%.  This 
concentration was used as the acceptance criteria for the samples.  Each sample was 
tested using either 4 or 6 total injections (with the first injection discarded from the 
results when averaged).  The results are shown in Table 2.5.  The 0.5 mL injection 
volume failed the acceptance criteria for each sample with the counts always being biased 
low at this injection volume.  It was determined that 4 injections (with the first injection 
discarded and not included in the averaging of the results), using 1 mL volume, were 
accurate for particle count.  The 1 mL injection volume resulted in low percent relative 
standard deviations (%RSD) for all samples tested. 
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Table 2.5.  Particle count results for the accuracy study using 2 and 15 µm. 
 
Stnd # Injections Inj vol (mL)
Mean 
Particles/mL
Standard 
Deviation %RSD
Acceptance criteria 
(particles/mL)
2 µm 4 0.5
0.5
0.5
0.5
2561 79 3 2700-3300
2 µm 4 1 2791 32 1 2700-3300
2 µm 6 2644 92 3 2700-3300
2 µm 6 1 2781 20 1 2700-3300
15 µm 4 2537 31 1 2700-3300
15 µm 4 1 2904 45 2 2700-3300
15 µm 6 2591 40 2 2700-3300
15 µm 6 1 2808 15 1 2700-3300  
 
2.1.3.2  Linearity 
The linearity associated with particle counts was evaluated by analyzing a series of 
particle concentrations, covering a range of particle size.  It was determined in the 
accuracy study that a 0.5 mL injection volume would not produce a count within the 
acceptable range.  Based on this information, 1 mL and 5 mL (USP suggested volume) 
injection volumes were evaluated.  A total of 4 injections were used (with the first 
injection result discarded).  A series of 5 dilutions were made using 2, 5 and 15 µm count 
standards as described previously in this report.  The tested particle dilutions ranged from 
1000 particles/mL to 25 particles/mL.  Tables 2.6 to 2.8 show the particle count results 
for each particle size standard tested.  The data tables include the standard deviation and 
percent relative standard deviation (%RSD) for the three injections.  In addition, the % 
difference from the resulting concentration versus the target concentration is calculated 
for each dilution level.  The % difference was always higher at the highest dilution 
(Dilution #5) because the concentrations were very low at this level.  Low counts such as 
this are approaching the noise of the system and are highly variable. 
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Table 2.6.  Results for the linearity test with the 2 µm standard (N=3). 
 
Stnd  Dil# 
Inj Vol 
(mL) 
Resulting 
Conc 
(particles/mL) 
Standard 
Deviation %RSD 
Target Conc 
(particles/mL) %Diff 
2 1 1 1064 45.79 4.302 1000 6 
2 2 1 564 18.6 3.30 500 13 
2 3 1 210 14.6 6.93 200 5 
2 4 1 102 8.50 8.37 100 2 
2 5 1 33 3.0 9.1 25 32 
                
2 1 5 1013 5.100 0.4625 1000 1 
2 2 5 599 9.34 1.56 500 20 
2 3 5 224 5.77 2.58 200 12 
2 4 5 114 3.70 3.25 100 14 
2 5 5 33 1.9 5.7 25 31 
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Table 2.7.  Results for the linearity test with the 5 µm standard (N=3). 
 
Stnd  Dil# 
Inj Vol 
(mL) 
Resulting 
Conc 
(particles/mL) 
Standard 
Deviation %RSD 
Target Conc 
(particles/mL) %Diff 
5 1 1 958 11.9 1.25 1000 -4 
5 2 1 470 21.0 4.47 500 -6 
5 3 1 193 17.2 8.90 200 -4 
5 4 1 103 18.6 18.0 100 3 
5 5 1 30 8.0 27 25 20 
                
5 1 5 1001 10.51 1.049 1000 0 
5 2 5 516 4.70 0.911 500 3 
5 3 5 206 8.16 3.96 200 3 
5 4 5 109 5.51 5.03 100 9 
5 5 5 29 2.1 7.3 25 16 
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Table 2.8.  Results for the linearity test with the 15 µm standard (N=3). 
 
Stnd  Dil# 
Inj Vol 
(mL) 
Resulting 
Conc 
(particles/mL) 
Standard 
Deviation %RSD 
Target Conc 
(particles/mL) %Diff 
15 1 1 969 11.4 1.17 1000 -3 
15 2 1 481 12.5 2.60 500 -4 
15 3 1 202 8.74 4.33 200 1 
15 4 1 102 7.23 7.07 100 2 
15 5 1 31 7.5 24 25 24 
              
15 1 5 1002 8.900 0.8881 1000 0 
15 2 5 487 4.69 0.962 500 -3 
15 3 5 205 15.1 7.37 200 3 
15 4 5 104 6.20 5.95 100 4 
15 5 5 33 0.70 2.1 25 33 
 
 
The data was also plotted, overlaying the resulting concentrations obtained for both 
injection volumes per sample dilution tested.  Figures 2.1 to 2.3 demonstrate that the 
same results were obtained regardless of the injection volume.  All samples, regardless of 
injection volume resulted in linear curves over the particle concentration tested.  The 
lines overlay perfectly, with very small error bars and good fit for each line (R2 values of 
at least 0.999), as shown in the plots.  The 1 mL injection was shown to be equivalent to 
the 5 ml injection volume under the test conditions used, which indicates that using a 1 
mL injection would provide particle counts in compliance with USP<788>.  The 
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concentration range tested is broad as would be expected when testing a variety of 
solutions, where very low counts might be encountered for a blank or very dilute protein 
solution and the higher counts (1000 particles/mL) are common for higher concentration 
protein solutions or stressed samples. 
 
Figure 2.1.  Plot of particle counts for 1 mL and 5 mL injection volumes, over a range of 
concentrations (dilutions) for the 2 µm standard.  Error bars represent ± 1 standard 
deviation (N=3). 
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Figure 2.2.  Plot of particle counts for 1 mL and 5 mL injection volumes, over a range of 
concentrations (dilutions) for the 5 µm standard.  Error bars represent ± 1 standard 
deviation (N=3). 
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Figure 2.3.  Plot of particle counts for 1 mL and 5 mL injection volumes, over a range of 
concentrations (dilutions) for the 15 µm standard.  Error bars represent ± 1 standard 
deviation (N=3). 
 
 
 
 
2.1.3.3  Precision 
Precision measurements were made for the 0.5 mL injection volume using a limited 
number of samples because the accuracy was less than desired.  The 1 mL injection 
volume, found to be the most suitable test volume, was analyzed for repeatability and 
reproducibility of the measurement.  In addition a set of injections at 5 mL (compendial 
volume) was performed for comparison using a limited data set.  The average cumulative 
counts (particles/mL) for 3 injections (4 injections were made, with the first being 
discarded) is shown in the summary table (Table 2.9).  The repeatability of the 
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measurement (average of runs performed on a single day), and the reproducibility of the 
measurement (average of runs over 3 days testing) were calculated. The cumulative 
counts for the appropriate size range were evaluated, where cumulative counts at 1.5 µm 
encompass the results for the 2 µm standard and cumulative counts at 10 µm encompass 
the results for the 15 µm standard.  The measurement error was captured in this testing, 
whereas the procedural error was not accounted for due to the nature of the sample 
preparation.  Table 2.10 is a summary of the average counts (particles/mL) for all 
injections per sample, averaged over all days of testing.   For all results, the standard 
deviation (SD) and percent relative standard deviation (%RSD) were calculated.  
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Table 2.10.  Particle count results for each sample, averaged over all days runs.  The 
standard deviation (SD) and percent relative standard deviation (%RSD) are reported.   
 
Sample Name 
Injection volume 
(mL) No. of Runs 
Avg 
particles/mL SD %RSD 
2 um, 25 p/mL 0.5 7 35 6.8 20 
2 um, 25 p/mL 1 9 36 4.2 12 
2 um, 25 p/mL 5 3 37 1.5 4.0 
2 um, 1000 p/mL 0.5 5 875 6.82 0.780 
2 um, 1000 p/mL 1 9 974 47.1 4.83 
2 um, 1000 p/mL 5 3 1009 6.055 0.6001 
15 um, 25 p/mL 0.5 7 24 4.0 17 
15 um, 25 p/mL 1 9 26 2.7 11 
15 um, 25 p/mL 5 3 25 1.8 7.0 
15 um, 1000 p/mL 0.5 7 879 19.7 2.24 
15 um, 1000 p/mL 1 9 907 48.4 5.34 
15 um, 1000 p/mL 5 5 988 7.40 0.749 
 
2.1.3.4  Specificity 
Mixtures of 2 and 15 µm particles were created (Stock 1 and 2) to determine the 
specificity of particle counting in a mixed sample.  The results showed that the larger 
particle size was greatly undercounted in the presence of the smaller particles, regardless 
of the ratio in counts between particle sizes (Table 2.11).  In addition, the injection 
volume did not affect the results.  This undercounting was unexpected and suggests that 
some optical condition is not ideal when the very small particles are present. 
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Table 2.11.  Particle count results for the mixed samples used in specificity testing.  
Results for both injection volumes and standard mixes (Stock 1 and 2) are shown.  The % 
difference from the target (target concentration expected for the Stock suspension) was 
also evaluated. 
 
Sample 
Injection 
Vol (mL) 
Total 
Counts/mL 
at 2 µm 
% 
Difference 
from 
target 
Total 
Counts/mL 
at 15 µm 
% 
Difference 
from 
target 
Stock 1  Target particle 
counts: 2µm=200p/mL, 
15µm=800 p/mL 
1 203 1.67 669 -16.4 
1 194 -2.84 504 -37.0 
5 209 4.66 482 -39.7 
5 207 3.64 474 -40.8 
Stock 2  Target particle 
counts:  2µm=800p/mL, 
15µm=200 p/mL 
1 769 -3.83 161 -19.7 
1 766 -4.25 151 -24.5 
5 811 1.33 130 -35.0 
5 796 -0.47 125 -37.5 
 
 
2.1.3.5  Robustness 
Since the HIAC is a light obscuration based system, air bubbles will be detected as 
particles, making degassing a critical step during sample preparation.  Samples were 
evaluated for the best mode of degassing and the amount of time needed for sufficient 
degassing of the solutions. Degassing conditions included letting the sample sit at 
ambient conditions, sonication or exposing to vacuum. 
Sample types included two standard formulation buffers (Form A and Form B) 
commonly used during biotherapeutic product development, particle free water and Form 
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B with 10 mg/mL BSA added.  The buffer formulations had viscosities similar to water.  
Samples were manually shaken with 30 inversions to introduce air to the system. 
A common method for degassing is to let samples sit under ambient conditions for a 
specified period of time.  The results for the samples allowed to sit include the T0 or 
initial particle counts for comparison to each sample type.  It was determined that for 
some of the samples, at least 5 min sitting would be needed for appropriate degassing.  
Results for all sample types, with sitting, are shown in Figure 2.3.  Sonication was an 
effective method for degassing and provided low counts after 30 seconds for most 
samples as shown in Figure 2.4, but it is not recommended for protein solutions since it 
can be aggressive enough to induce some aggregation.  Vacuum degassing provided 
consistent and low particle counts for all sample types after 30 seconds, and is gentle on 
protein solutions (Figure 2.5). 
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Figure 2.3.  Particle counts for all samples, degassing by allowing the sample to sit 
unperturbed.  The error bars represent ± 1 standard deviation, N=3. 
 
 
Figure 2.4.  Particle counts for all samples, degassing through the use of sonication.  
Particle count values are included since the values are very low for most samples.  The 
error bars represent ± 1 standard deviation, N=3. 
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Figure 2.5 .  Particle counts for all samples, degassing through the use of vacuum.  Note 
that all counts are very low, even at 30 sec.  The error bars represent ± 1 standard 
deviation, N=3. 
 
 
 
 
2.1.4  Discussion  
The 1 mL injection was shown to be equivalent to the 5 ml injection volume under the 
test conditions used.  The 5 mL injection volume is the accepted volume per USP<788>.  
This study demonstrates that using a smaller volume, down to 1 mL per injection during 
sub-visible particle analysis, would provide comparable results. 
 
Specificity studies using mixtures of 2 and 15 µm particles were used to evaluate the 
effect of mixed particle size distributions on count accuracy.  The results indicated that, 
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in the presence of small particles, larger particles were undercounted.  This phenomenon 
occurred at 1 mL and 5 mL injection volumes and with different ratios of smaller to 
larger particles.  This finding was unexpected and will be investigated in the future.  It 
suggested that the detection mechanism (based on light obscuration) can be affected by 
the presence of very small particles. 
 
During the sample preparation, it’s important that proper degassing is employed.  It 
should be noted that more time may be needed for high concentration and more viscous 
samples.  When not using standard formulation buffers at low protein concentration, it is 
suggested that a quick degassing study be performed to ensure the amount of degassing is 
appropriate for the sample type.  When there is not enough sample for this type of study, 
it is suggested that 2 minutes of vacuum degassing be used.  A quick check under low 
magnification using an optical microscope to determine if the test solution is free from 
bubbles can also be performed.  If larger bubbles are still present, additional vacuum 
degassing may be required. 
In summary, the method recommended would utilize the laboratory conditions and 
environmental checks as described in USP<788>.  A 1 mL injection volume would be 
employed, with 4 injections made, discarding the first.  The sample would be prepared by 
vacuum degassing for 2 min before analysis.  Data would be collected from 2-100 µm, 
with an appropriate system calibration performed before analysis. 
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2.1.5  Summary 
The studies outlined in this section demonstrated the acceptability of monitoring particle 
counts using a lower injection volume than indicated in USP<788>.  In addition, the 
parameters described allow for collecting particle count information in the 2-10 µm size 
range.  The parameters tested indicated this approach was accurate, linear, precise and 
robust over the 2-100 µm size range using a 1 mL injection volume.  The specificity of 
particle counting should be investigated further, probing the effect of having very small 
particles present in a sample.  This phenomenon could account for some discrepancies 
between light obscuration and micro-flow imaging when analyzing protein solutions, 
where it is common to detect a great deal of very small particles. 
 
2.2  Understanding the Effect of Particle Transparency on Particle Count 
Differences Between Micro-flow Imaging and Light Obscuration. 
Protein aggregation and the presence of particulate matter are of great interest during the 
development of biologic drug products.  There has been much interest in the 
characterization of protein particles, particularly in the sub-10 µm size range.  There are 
two popular techniques for obtaining particle count information in this size range:  light 
obscuration and dynamic flow imaging.  There are, however, significant differences in 
the particle count results when comparing these techniques.  It is believed that these 
differences are primarily due to the transparency of protein particles, suggesting that 
dynamic flow imaging is more sensitive to detecting these types of particles.  A study 
was performed to further investigate this phenomenon, using stable standard materials 
with varying refractive indices (a measure of transparency).  In addition, the materials 
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tested have differences in morphology, so this variable could also be studied for its effect 
on detection when evaluating these two counting techniques.  The results suggest that 
both particle transparency and particle size play a role in the detection differences 
between light obscuration and dynamic flow imaging.  Particle morphology does not 
seem to have any effect.  Dynamic flow imaging provides a good orthogonal method for 
the characterization of sub-visible particulates, but caution must be applied when 
comparing to light obscuration results, especially when analyzing sub-10 µm semi-
transparent particles. 
 
2.2.1 Introduction 
Protein aggregation is of great interest and concern in the development of biologic drug 
products.  Recently, there has been a lot of discussion around the characterization of 
particles in the sub-visible size range, with growing interest in the particles that are below 
10 µm.  The heightened interest in characterization is supported by lack of data around 
the immunogenic effects of sub-visible protein particles in drug products [22].  To date, 
there is no particular property of a protein that can be identified as an obvious predictor 
of immunogenicity, however aggregation leading to protein particulates has been the 
focus of many recent discussions in this area [23].  Protein aggregate particle size can be 
categorized into three major size classifications as shown in Figure 2.6.  Three classes of 
particle size ranges were chosen to minimize the number of categories used when 
discussing particulate matter.  Furthermore, the size ranges per class described in this 
paper, are grouped based on the characterization techniques that might be employed, and 
their analytical limitations.  The technologies available for size and count 
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characterization, based on their limits of detection, fall nicely within these size ranges.  
The sub-micron class is usually characterized using techniques such as size-exclusion 
chromatography (SEC) and dynamic light scattering (DLS), and much more recently, 
nanotracking instrumentation.  The sub-visible particle size class is usually characterized 
by techniques such as light obscuration, dynamic flow imaging, optical microscopy and 
electrical resistance (eg., Coulter Counter method).  The visible class is usually 
characterized by visual inspection, but can be analyzed using light diffraction to obtain 
particle size distribution information, and optical microscopy techniques for obtaining 
particle size and count, as well as some compositional information. 
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Figure 2.6.  Schematic showing the three ranges that particle size can be divided into.  
This classification aids in the ability to quickly label a particle group and determine the 
best characterization approaches to use.  The circled region encompasses the sub-visible 
to visible range, which is the focus of this report. 
 
 
 
There have been many studies comparing the sub-visible particle counts from two 
primary techniques, dynamic flow imaging and light obscuration.  These techniques are 
used routinely to analyze biologic drug product formulations for particle load at specific 
size ranges [24].  Dynamic flow imaging involves a sample flowing past a field of view 
within a magnification system.  Digital images of the sample are captured and analyzed 
in real time.  A popular instrument used for flow imaging is the Brightwell Micro-Flow 
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imaging system.  Light obscuration particle count analysis is an established method, cited 
in several compendia as the means for obtaining sub-visible particle counts.  A popular 
instrument used for light obscuration is the HIAC instrument. 
 
All the techniques cited earlier have limitations with the method of analysis for protein 
particles.  For instance, it has been shown repeatedly that there is a discrepancy between 
counts obtained by dynamic flow imaging and light obscuration [25, 26].  Several factors 
can affect the sensitivity of detection and resulting particle counts for these particle 
analyzers, including sphericity of the particles, transparency and fragility to shear stress.  
A popular explanation for the count differences is that the flow imaging systems are 
better able to detect semi-transparent particles with better sensitivity than light 
obscuration [27].  There are some contradictions in the literature to this hypothesis, where 
transparency did not seem to affect particle counts for all studies performed. 
 
Both the dynamic flow imaging and light obscuration techniques are dependent on the 
interaction of light with the medium the particles are suspended in, as well as the particles 
themselves.  In these instruments, light can be considered as waves that will travel at 
different speeds through different media.  In addition, the light will interact with the 
particles causing some degree of change in speed of propagation, as well as bending 
during transmission through the particle, and reflection from the particle.  The index of 
refraction is used as a description of this interaction between light and the particle.  The 
transparency of a particle is related to its refractive index.   
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Refractive index is defined as: 
n = velocity of light in a reference medium / velocity of light in medium of 
interest 
 
This light is transmitted.  Another interaction of light with an object is reflection.  The 
amount of light reflected off an object is related to its reflectivity (R).   
 
The reflection parameter (R) is defined below, and is based on a normal incidence angle 
and is dependent upon the refractive indices of the object (n1) and the medium it’s in 
(n2).  For common glass in air (n1= 1, n2=1.5) there’s about a 4% reflection of the light. 
This interplay of light and objects, or particles for our purposes, demonstrates that there
are several parameters which will affect how a particle is detected in a system based on 
light interaction.
 
 
 
 
R = [(n1-n2)/(n1+n2)]2  
 
The standard way to calibrate a particle counting system is to use latex microspheres, 
with a refractive index of 1.51.  It has been reported that a protein particle can have 
refractive indices ranging from approximately 1.39 to 1.45 [28].  The refractive index is 
related to how transparent a particle will appear to the counting instrument, and will vary 
with protein particle properties such as degree of hydration and overall size and shape of 
the particle. 
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In this study, we attempted to investigate the effect on detection by dynamic flow 
imaging and light obscuration using standard materials with very different refractive 
indices.  Standard materials that mimic the optical properties of proteins are not currently 
available, and protein particles were not used since their properties, such as size and 
morphology, can change during analysis.  It was desired to choose standard materials that 
were stable and dispersible in aqueous media, within an acceptable size range, and of 
varying refractive indices.  The refractive index values for protein particles range from 
approximately 1.39 to 1.45, so for this study we chose materials with similar as well as 
significantly different refractive indices.  The standard particles analyzed were stable and 
not affected by shear forces.  Particle shape also varied for these materials and must be 
considered when evaluating the results. 
 
The standard materials were analyzed using both the HIAC and Brightwell 
instrumentation.  Differences in particle counts were evaluated for each instrument.  In 
addition, the variability for chosen size ranges was also evaluated, as a function of the 
standard particle physical properties.  Based on the current thinking, a sample with a 
large difference in refractive index from its suspending media, should provide similar 
results whether analyzed using a HIAC or Brightwell.  This assumes that particle 
transparency is the primary factor in the discrepancies seen with these two instruments. 
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2.2.2 Materials and Methods 
2.2.2.1  Materials 
The HIAC/ROYCO model 9703 particle counter (Hach Ulta), equipped with a HRLD-
150 sensor was used for all light obscuration analyses.  For dynamic flow imaging, the 
Brightwell DPA4200 (Brightwell Technologies, Inc., Canada) was used throughout.  
Particle free water (MilliQ) was used for all system flushing and for environmental 
checks (refractive index 1.33).  Phosphate buffered saline, 1X at pH 7.2 (Gibco) was used 
as the suspension media for the silicon carbide and kaolin materials.  NIST traceable 
Count-Cal polystyrene microsphere standards with a 15 µm nominal diameter (purchased 
from Thermo-Fisher) were used (these particles have a refractive index of 1.59 at 589 
nm).  Kaolin, NIST standard #8570, was used (with a refractive index of 1.56).  Silicon 
carbide, standard #F1200-93 (Sympatec) was also used as a standard test material (with a 
refractive index of 2.55). 
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A table of the properties of the reference materials is shown below for ease in comparing 
the materials. 
 
Material Refractive
Index
Primary 
Particle Size
Range
Morphology
Polystyrene 
microsphere
1.59 15 um 
monomodal
Spherical
Kaolin 1.56 1-10 um Plate like
Silicon Carbide 2.55 2-20 um Irregular, 
laths
 
 
2.2.2.2  Preparation of Standard Solutions 
The latex microspheres come as a well characterized suspension with a certified particle 
count of 3000 particles/mL.  This material was used as-is from the container. 
Kaolin and silicon carbide were provided as dry powders.  Suspensions of each material 
were made, taking care to keep the concentrations low enough to not saturate the 
detection systems on either the HIAC or Brightwell instruments.  Samples were dispersed 
in 1X PBS.  Initially, the suspensions were prepared at 1.5 mg/100mL.  These samples 
proved too concentrated for the detection systems for both HIAC and Brightwell.  This 
stock suspension was further diluted 1:100 to provide the working suspensions used in 
the study.  Since the long term stability of the suspensions was not investigated, the 
suspensions were used within 24 hours of preparation and the samples were checked by 
optical microscopy at the beginning and end of the study. 
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2.2.2.3  Optical Microscopy 
All samples were examined by light microscopy using a Nikon Eclipse ME600 
microscope to assess the dispersion properties as well as particle size and morphology.  
Images were captured and analyzed using a Spot Insight CCD camera and ImagePro Plus 
software. 
 
2.2.2.4  Light Obscuration 
Samples were analyzed using a Hach HIAC, model 9703 light obscuration instrument.  
Particle size was monitored to cover the range from 1.5 to 100 µm.  Samples were tested 
using 4 runs, discarding the first run.  An analysis volume of 1 mL was utilized per run. 
 
2.2.2.5  Brightwell 
Samples were analyzed using a Brightwell model DPA4200 micro-flow imaging system.  
An analysis volume of 1 mL was used for all samples.  The illumination of the system 
was optimized using the 1X PBS diluent used to prepare the samples.  The diluent was 
filtered through a vacuum filtration unit containing a 0.2 µm cellulose acetate membrane, 
before use. 
 
2.2.3 Results 
It has been previously reported that the largest differences in particle counts between the 
dynamic flow imaging systems and light obscuration lies in the <10 µm size region [29].  
Furthermore, it has been suggested that the Brightwell may be providing higher counts 
versus the HIAC due to attrition of aggregated protein particles, creating smaller particles 
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that account for the higher differences between techniques at the lower particle size [27].  
Samples containing protein particles have been studied most.  It’s been shown that 
protein particles vary in transparency with particle size and method of generation [27].  
However, the transparency values reported are based on the intensity results obtained 
using the Brightwell software.  It’s important to note that these small particles, less than 
10 µm and even more significantly for less than 5 µm, will have very limited resolution 
using a dynamic flow imaging system.  For this study, the standard materials tested were 
evaluated using the Brightwell and HIAC, but were also characterized using static optical 
microscopy.  The materials used in this study were chosen to help probe the idea of 
particle attrition since these particles are not changing in solution nor are they going to be 
susceptible to the low shear forces applied during analysis using either technique.  The 
particles tested in this study were in the size range of most interest (less than 10 - 15 µm). 
 
As stated previously, the standard materials were chosen for their differences in physical 
properties including refractive index.  Kaolin and the latex microsphere standards have 
similar refractive indices but differ in morphology.  Silicon carbide has a significantly 
different refractive index and morphology than the other two standards. 
 
Optical microscopy was used in the characterization of these standard materials.  Figures 
2.7- 2.9 show the particle characteristics for each standard material tested.  As shown, 
there were differences in the morphology of these particles, with the latex standards being 
perfectly spherical.  The kaolin particles had a plate-like morphology with the majority of 
the particles in the 1-10 µm size range.  The silicon carbide material contained particles 
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that were irregular in shape, with some small lath shaped particles.  These particles were 
primarily in the 2-20 µm size range.  As stated previously, the refractive index values for 
these samples varied, with silicon carbide having a significantly different refractive index 
than the other two samples. 
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Figure 2.7.  Photomicrograph of the polystyrene standard material, showing the sphericity 
of these particles.  Sample was tested as-is from the original vial.  200X total 
magnification. 
 
 
Figure 2.8.  Photomicrograph of the kaolin standard material, suspended in the PBS 
buffer.  These particles didn’t exhibit a great deal of contrast from the PBS diluent.  400X 
total magnification. 
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Figure 2.9.  Photomicrograph of the silicon carbide standard material, suspended in the 
PBS buffer.  These particles had good contrast from the PBS diluents.  400X total 
magnification. 
 
 
All three standard materials were analyzed by both counting techniques.  The particle 
counts over a broad range of particle sizes were evaluated.  The counts for each sample, 
per size range, were plotted as shown in Figures 2.10 to 2.12.  The particle counts for the 
15 µm polystyrene microsphere standard were compared using each technique.  These 
particles had a fairly tight monomodal distribution with a nominal diameter of 15 µm.  
The counts obtained were very similar when looking at the size range encompassing the 
majority of the particles (10-25 µm).  There was some difference at the 1-2 µm size 
range, with the Brightwell having higher counts.  These counts could be due to fines in 
the sample or other external particulate matter not related to the standard material, but 
with properties allowing for better detection by the Brightwell.  The particle size was too 
small to be well resolved by the Brightwell imaging system or by optical microscopy.  
All three standard materials were run in triplicate using each instrument.   
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The precision of the analyses is shown in Table 2.12.  As expected, there was much 
higher variability with lower particle counts, due to the statistical inaccuracies in small 
sample sizes.  However, it appears that counts obtained per size range for the silicon 
carbide samples were more variable than kaolin.  The polystyrene standard material has 
low variability by both techniques in the 10-25 µm size range. 
 
The silicon carbide sample (Figure 2.11) resulted in differences between the two 
techniques, especially in the 2-5 µm size range, where a large population of the particles 
reside.  The kaolin sample distribution (Figure 2.12) resulted in significant differences 
between techniques when comparing particle counts in the 1-5 µm size range, again 
where the majority of the particles reside.  It should be noted, however, that trends in the 
size distributions were similar between instruments.  The shape of the size distributions 
obtained by both techniques were similar, but the overall counts differ. 
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Figure 2.10.  Plot of the particle counts per size range for the polystyrene microsphere 
standard material.  Both Brightwell and HIAC results were compared.  The error bars 
represent ± 1 standard deviation, N=3. 
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Figure 2.11.  Plot of the particle counts per size range for the silicon carbide standard 
material.  Both Brightwell and HIAC results were compared.  The error bars represent ± 
1 standard deviation, N=3. 
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Figure 2.12.  Plot of the particle counts per size range for the kaolin standard material.  
Both Brightwell and HIAC results were compared.  The error bars represent ± 1 standard 
deviation, N=3. 
0
5000
10000
15000
20000
1-<
2µ
m
2-<
5µ
m
5-<
8µ
m
8-<
10
µm
10
-<2
5µ
m
25
-<5
0µ
m
50
-<1
00
µm
Particle Size Range
Pa
rti
cl
es
/m
L
Kaolin Mean HIAC
Kaolin Mean BW
 
65 
 
 
Table 2.12.  Precision of count measurements for all standard materials tested.  Counts 
were classified by particle size range.  Results for both the Brightwell and HIAC are 
listed. N=3. 
Particle Size 
Range - HIAC 
Mean SiC 
particles/mL 
(N=3) %RSD 
Mean Kaolin 
particles/mL 
(N=3) %RSD 
Mean PS 
Standard 
particles/mL 
(N=3) %RSD 
1-<2µm 319 11 1705 4 134 58 
2-<5µm 1312 17 1062 12 62 77 
5-<8µm 180 35 88 21 14 93 
8-<10µm 10 44 11 31 5 40 
10-<25µm 5 26 8 11 2805 2 
25-<50µm 0 N/A 0 N/A 3 67 
50-<100µm 0 N/A 0 N/A 0 N/A 
Particle Size 
Range - 
Brightwell             
1-<2µm 513 43 17271 10 824 9 
2-<5µm 2695 26 5231 8 214 4 
5-<8µm 796 44 325 5 26 19 
8-<10µm 31 34 38 25 3 33 
10-<25µm 12 44 27 39 2513 5 
25-<50µm 0 N/A 2 100 2 50 
50-<100µm 0 N/A 1 173 1 100 
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Although counts obtained by the Brightwell were higher in each case, the magnitude of 
that difference varied with the type of sample tested.  Table 2.13 lists the absolute 
difference in counts, per size range, for each sample, as a ratio of the Brightwell results to 
the HIAC results.  These differences were also represented graphically, as shown in 
Figure 2.13.  As seen in the plot, there was approximately a 10 fold higher count obtained 
for kaolin in the 1-2 µm size range when comparing the Brightwell to the HIAC.  This 
difference was about 6 fold for the polystyrene standard and less than 2 fold for the 
silicon carbide material.  These results are explainable since the silicon carbide had the 
highest refractive index and should provide better contrast against the surrounding media.  
The difference continued to decrease as the particle size increases.  This data suggests 
particle size and refractive index play a role in how the particles are detected by the two 
instruments. 
The results obtained using these standard materials suggest there are differences in the 
two counting techniques, and the difference appears to be dependent on particle size, with 
lower sizes having larger differences.  However, it also appears that as the particle 
refractive index increases, the difference in counts between the techniques decreases at 
lower sizes.  As the particle refractive index increased, the contrast to its surrounding 
media also increased. 
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Table 2.13.  The absolute differences in mean particle counts (as a ratio of Brightwell to 
HIAC particles/mL) per size range (N=3).  Note the decreasing magnitude in count 
difference as the particle size increased. 
Size 
Range 
Silicon 
Carbide Kaolin 
PS 
Standard 
1-<2µm 1.6 10.1 6.1 
2-<5µm 2.1 4.9 3.5 
5-<8µm 4.4 3.7 1.9 
8-<10µm 3.2 3.4 0.6 
10-<25µm 3 4 0.9 
25-<50µm 0 2 0.7 
50-<100µm 0 1 1 
 
Figure 2.13.  The absolute differences in counts per size range for all three standard 
materials.  Difference shown is the ratio of Brightwell to HIAC results.  The graph shows 
how differences are minimized with increasing particle size. 
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The particle morphology does not appear to play a significant role in the count 
discrepancies.  Differences in the precision of the measurements when comparing silicon 
carbide and kaolin were observed.  A larger sample size would need to be tested to 
determine how significantly the precision of the measurement is affected by particle type, 
using both instruments. 
 
2.2.4 Discussion  
Differences in particle counts for all standard materials tested were largest in the <10 µm 
size range.  The differences between the Brightwell and HIAC were more pronounced as 
the refractive index of the particle approached that of the media it was suspended in.  
Particle shape was not a significant factor, when comparing spherical and more plate like 
morphologies. 
 
The variability observed with silicon carbide may be due to the high refractive index of 
this material or may be due to the particle shape.  Further investigation is needed to 
understand this phenomenon and ensure that the dynamic imaging system used can detect 
particles of interest, regardless of shape or optical properties.  Especially in the cases 
where the data obtained from these systems is being compared to light obscuration 
results. 
 
It should also be noted that interesting findings were obtained during development of the 
low volume light obscuration method using the HIAC, as discussed previously.  In the 
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specificity study, 2 and 15 µm particle mixtures were created to evaluate the effect of 
mixed particle sizes in count accuracy.  The results indicated that, in the presence of 
small particles, larger particles were undercounted, regardless of the injection volume or 
ratio of amount of small to larger particles tested.  The results suggest that having very 
small particles in the sample can alter the detection efficiency in light obscuration 
methods.  Particle size/count standard materials, such as latex microspheres, are very well 
defined.  The majority of the particles in the sample are within the size range specified on 
the label.  For instance, with a 15 µm standard material, the great majority of particles 
will be around that nominal size value.  Protein solutions, however, have a large 
population of very small particles (1-2 µm) as regularly detected using flow imaging.  
These very small particles could interfere with accurate counting using a light 
obscuration technique.  This may play a bigger role in particle count discrepancies 
observed between light obscuration and dynamic imaging versus the transparency or 
refractive index of a particle.  Future studies will be performed to better understand the 
effect of large populations of very small particles on the counting efficiency of larger 
particles. 
 
2.2.5 Summary 
Dynamic flow imaging (eg., Brightwell MFI) can be used as an orthogonal technique for 
light obscuration (eg., HIAC) in obtaining sub-visible particle count information.  The 
results obtained with these techniques might not agree in absolute counts but, in most 
cases, the trends in counts over a range of particle sizes will be similar.  In addition, flow 
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imaging can provide additional information on the shape and type of particles tested, 
which can enhance the data obtained by light obscuration. 
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Chapter 3.  Enhancing the Microscopic Visualization of 
Protein Aggregates by Using a Protein Specific Dye 
 
3.1  Introduction 
There is much discussion around the evaluation of protein particles in the sub-visible to 
visible size range.  This is of particular interest when analyzing biologic compounds due 
to the lack of data around the immunogenic effects of protein particles in drug products 
[23].  The range of particle sizes can be categorized as sub-micron, sub-visible and 
visible, as shown in Figure 2.6.  The submicron range includes oligomers and multi-mer 
aggregates.  The sub-visible size range varies depending on the detection system, but in 
general can be described as particles in the 1-100 µm range.  The visible particle size 
range can be described as particles >100 µm.  Visual inspection is traditionally used for 
detection of visible particles in a sample.  Sub-visible particles, however, rely on 
techniques such as light obscuration and dynamic flow imaging for detection. 
 
Dynamic flow imaging involves a sample flowing past a field of view in a magnification 
system.  Digital images of the sample are captured and analyzed in real time.  A popular 
instrument used for dynamic imaging is the Brightwell micro-flow imaging system. 
Light obscuration particle count analysis is an established method, cited in several 
compendia as the means for obtaining sub-visible particle counts, where sub-visible is 
described here as particles less than 100 µm.  A popular instrument used for light 
obscuration is the Hach HIAC instrument. 
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Techniques such as light obscuration and dynamic flow imaging can require large 
amounts of sample for proper analysis.  Optical microscopy is traditionally a very 
material sparing technique, and would be preferred when very little sample is available, 
as is sometimes encountered during the early development stage of biologic products. 
Parenteral products have to meet particle load requirements as outlined in the United 
States Pharmacopeia (USP) <788>.  The compendium outlines the use of light 
obscuration analysis for determining particle counts in the sub-visible region.  If the 
sample fails this testing, an alternative test using optical microscopy should be employed.  
This is where complications can occur when analyzing protein aggregates.  Protein 
particles are amorphous, and can vary significantly in rigidity and transparency.  Many 
protein particles are very flexible and very transparent, with refractive indices reported in 
the 1.4-1.5 range.  When employing membrane microscopy, the sample is filtered onto a 
depth filter capturing the particles on the filter surface for microscopic examination.  
Protein particles will embed in the filter membrane and due to their transparency, can be 
impossible to detect using standard fiber optic lighting as outlined in the compendia.  
Protein particles can be difficult to visualize, even when using Nucleopore type filters 
unless specialized lighting is employed, making the approach difficult, even for the 
experienced microscopist.  At times, very labor intensive isolation techniques are needed 
to capture protein particles for simple visual examination. 
 
The characterization of particles to determine if they are proteinaceous usually involves 
additional spectroscopic analysis such as FTIR-microscopy or Raman spectroscopy.  
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These techniques can be time consuming and may require specialized skills for proper 
sample preparation.  The possibility of enhancing the contrast and identification of 
protein particles on a filter membrane by using visible dyes was evaluated.  Fluorescent 
dyes such as Nile Red were evaluated but required the use of a fluorescent microscope 
and particle isolation was not user friendly.  Using a visible dye would provide an easy 
and quick approach for characterization.  Here, the dye TBPE (3’, 3’’, 5’, 5’’-
tetrabromophenolphthalein ethyl ester was evaluated because it has been used for the 
qualitative determination of the presence of protein in samples [30].  Further research 
showed the use of the dye for quantitative analysis of the relative amounts of serum and 
spinal fluid proteins.  Two solvents, ethanol and methanol, were evaluated for creating 
the dye solution, as previously published [31]. 
 
The feasibility of applying the dye to enhance contrast of filtered protein particles, which 
could then be analyzed by image analysis techniques, was also investigated.  For this 
study, a monoclonal antibody (mAb) was used, labeled as mAb A.  mAb A was stressed 
by allowing to incubate overnight at 25 ºC before use. 
 
3.2  Materials and Methods 
The visible dye, TBPE (3’, 3’’, 5’, 5’’-tetrabromophenolphthalein ethyl ester, Fluka 
#86778) was used to enhance visualization of protein aggregates (structure shown 
below).  This dye was reconstituted in either ethanol or methanol.  A Nikon SMZ8000 
stereomicroscope was used for observing samples/filter membranes.  All solutions were 
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filtered using a Millex Durapore PVDF filter unit, 0.22 µm.  Protein samples were 
filtered onto a Nucleopore filter membrane (0.4 µm) for visualization. 
Model protein solutions included bovine serum albumin (BSA) and ovalbumin, 
reconstituted using 1X PBS, pH 7.2 (Gibco). 
 
TBPE 
C22H14Br4O4 
MW:  661.96 g/mol 
Structure 3.1 
3.2.1  Preparation of Protein Solutions 
A solution of mAb (mAb A) was made at 1 mg/mL in a formulation buffer.  This protein 
solution, greater than 1 yr old, and additionally stressed by placing at 25 ºC overnight, 
was used.  Some visible aggregates could be observed in the solution before use. 
3.2.2  Preparation of Dye Solutions 
Both methanol and ethanol have been used as diluents for TBPE solution preparation.   
Both solvents were evaluated to determine which might prove best when adding to 
protein solutions.  Solutions of dye were made at 0.02% w/w dye in alcohol. 
It has been shown that protein/TBPE binding was stable for at least 60 min [32].  
Although the referenced work used BSA and was performed to determine 
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spectrophotometric stability, the time during steady color formation was used as a 
guideline for this study.  Dye solutions were added to protein solutions at 1% v/v.  All 
protein/dye solutions made were used within 1 hour of preparation. 
A blank dye solution was also prepared using the ethanol dye solution at 10% in 1X PBS.  
This solution was analyzed by flow imaging to understand the particle counts that might 
be attributed to a blank sample. 
3.2.3  Filtration and Optical Microscopy 
When applicable, dye solutions were added to the protein solutions and allowed to 
incubate for approximately 1 minute before filtration. 
Protein solutions were filtered onto the 0.4 µm filter membranes, under clean conditions 
in a laminar flow hood.  Membranes were transferred to cleaned petri dishes and allowed 
to dry before viewing by microscopy. 
 
3.3  Results 
TBPE was chosen as the visible dye to enhance protein aggregate contrast when viewed 
by microscopy.  This dye has been reported to specifically interact with protein, resulting 
in a colorimetric change [30].  It is believed that the dye interacts with protein through 
the ester group.  The ester, in the presence of the protein particles, has a blue color, 
thought to be due to the formation of a salt-like adsorption compound, which is not 
affected by exposure to weak acid.  The blue color will persist with proteinaceous 
particles after being washed with weakly acidic solutions.  This reaction appears to be 
specific for proteins and some alkaloid compounds, when in large amounts.  This 
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specificity makes the dye an ideal candidate for enhancing the visual contrast of protein 
particles.   
Dynamic flow imaging was used to evaluate the interaction of the dye with the model 
protein systems evaluated.  The technique was used to look at the change in particle 
counts of neat protein solution versus in the presence of dye.  The contact time of the dye 
and protein was relatively short, but any increase in particle counts due to dye 
interactions were evaluated to ensure it was not inducing aggregate formation. 
Table 3.1 lists the particle counts obtained by flow imaging for all particles from 1-100 
µm,  for all samples tested.  Ovalbumin and bovine serum albumin were tested in 
dye/methanol and dye/ethanol solutions.  The methanol solution provided higher counts, 
suggesting aggregation had occurred.  The dye solution in ethanol was also analyzed to 
confirm background counts.  The contribution of dye solution toward particle counts was 
relatively low, as listed in Table 3.2.  This blank dye solution contained very little counts 
and was not subtracted from any results.  The particle counts for each sample were also 
displayed graphically (Figure 3.1).  A review of the results indicated there was instability 
with ovalbumin when exposed to the dye/methanol solution, as demonstrated by the large 
increase in particle counts for ovalbumin in dye/methanol when compared to ovalbumin 
solution in PBS.  There was an approximately 2-3 fold increase in particle counts for 
ovalbumin in dye/ethanol solution compared to an approximately 50-500 fold increase in 
particle counts for ovalbumin in dye/methanol solution.  The dye/methanol solution did 
not have as acceptable results as the dye/ethanol solution. 
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Table 3.1.  Particle concentrations (particles/mL) for each solution over a range of 
particle sizes, from 1 to 100 µm. 
Size Range BSA 
BSA + 
dye/methanol 
BSA + 
dye/ethanol OA 
OA + 
dye/methanol 
OA + 
dye/ethanol 
1-<2µm 827 506 739 1410 822246 3328 
2-<5µm 370 175 134 419 256938 1431 
5-<8µm 35 50 16 152 71356 358 
8-<10µm 4 16 4 49 24190 115 
10-<25µm 9 31 12 87 34577 175 
25-<50µm 2 5 1 13 619 22 
50-<100µm 0 0 0 1 11 3 
BSA:  bovine serum albumin 
OA:  ovalbumin 
Table 3.2.  Particle concentrations (particles/mL) for the blank/dye solution in ethanol 
over a range of particle sizes.  Due to the low counts, no blank subtractions were 
performed. 
Size Range Blank (dye) 
1-<2µm 134 
2-<5µm 56 
5-<8µm 23 
8-<10µm 5 
10-<25µm 8 
25-<50µm 0 
50-<100µm 0 
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Figure 3.1.  Particle concentrations (particles/mL) for each solution over a range of 
particle sizes, from 1 to 100 µm, as determined by flow imaging.  Error bars represent 1 
standard deviation. 
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In addition, optical microscopy/image analysis was employed to observe the amount of 
proteinaceous particles on the filter membrane after exposure to the dye/methanol 
solution and filtration.  Figures 3.2 to 3.5 are images of representative areas on the filter 
membranes.  No particles were detected in the BSA solution (Figure3.4) which agrees 
with micro-flow imaging results.  The ovalbumin sample contained fibrous protein 
particles.  Using microscopy, the elongated fibrous nature of the particles was easily 
detected. 
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Figure 3.2.  Photo showing the ovalbumin particles on the filter membrane, after 
exposure to dye/methanol (15X magnification).  The fibrous protein particles are easily 
seen on the filter membrane. 
 
 
Figure 3.3.  Photo showing the ovalbumin particles on the filter membrane (45X 
magnification) 
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Figure 3.4.  Photo showing the lack of particles on the filter membrane for the BSA 
sample (45X magnification) 
 
 
Figure 3.5.  Photo showing a foreign fiber on the filter membrane under coaxial lighting 
(75X magnification).  The particle is easily identified as a foreign particle due to the 
birefringence under the coaxial lighting along with lack of dye uptake. 
 
 
Because it was determined that dye solutions made using ethanol are less stressful to 
protein solutions, this dye composition was used to evaluate enhanced contrast of mAb A 
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aggregates after filtration onto a nucleopore membrane.  It should be noted that this 
conclusion using ethanol may not apply to other classes of proteins, and was used for 
mAb A due to the hydrophobic nature of the surface of this class of proteins.  A similar 
evaluation would be warranted if other classes of protein were evaluated. 
Protein aggregates could be seen visually on the filter.  The first attempts at an automated 
detection were performed.  The filter was dried and scanned using a BioRad 
densitometer.  The filter image before and after count analysis is shown in Figure 3.6.  
The filter membrane had a pale blue background with darker blue areas representing the 
protein aggregates.  There was sufficient contrast for the densitometer to detect the 
aggregates and ‘mark’ them for counting (dark blue squares on bottom image, Figure 
3.6).  The system was able to distinguish protein aggregates from background, and 
provide particle count information in the form of number of blue spots on the filter (519 
particles counted).  Using a visible dye along with an image analysis technique was a 
feasible approach for characterizing protein aggregates.  Further studies will be 
performed using more sophisticated image analysis techniques to enhance contrast and 
analysis of the particle population. 
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Figure 3.6.  mAb A solution, filtered and dyed for enhanced contrast, before (top) and 
after (bottom) counting the particles. 
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3.4  Discussion 
 There are many advantages to using a dye to enhance the contrast of protein particles 
when viewed microscopically.  Because of the transparency and flexibility of protein 
particles, they were not easily viewed on a filter membrane.  Adding a visible dye, 
allowed for quick evaluation of the particle load as well as morphology.  In addition, 
because TBPE is a protein specific dye, it allowed for rapid assessment of whether a 
particle is proteinaceous.  Silicone oil and semi-solid particle contaminants can appear as 
transparent and flexible particles but will not retain the dye after washing with a mildly 
acidic solution as has been discussed in the literature and demonstrated in previous 
experiments (images not provided) [30]. 
The approach for particle visualization described here can be used as an orthogonal 
method for light obscuration or flow microscopy, or visual inspection testing.  The 
approach would cover a very broad range of particles sizes, limited only by the 
magnification achievable with the microscope used. 
Another advantage of this approach was the ability to characterize particles using 
extremely small volumes, as low as a few drops of solution if desired.  For the example 
described, 1 mL of solution was filtered but the upper limit of filterable volume will only 
be limited by the abundance of particles in the test solution.  With very high particle 
concentrations, it will be necessary to limit the volume filtered to create a monolayer of 
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particles on the filter membrane.  Particulate matter can be captured on a filter membrane 
for characterization of size, shape and composition. 
3.5  Summary 
The use of a visible dye to enhance visual contrast and provide an indication as to 
whether the material is proteinaceous, has been shown to be feasible.  This technique 
allows for rapid analysis of particle abundance, morphology and type. 
 
An area for future investigation will be to apply this approach to the quantitative analysis 
of protein particles in conjunction with automated image analysis. 
 
85 
 
Chapter 4.  Silicone Oil and Protein Interactions 
 
Impact of silicone oil on protein aggregation formation/ morphology 
under pharmaceutically relevant conditions 
 
4.1  Introduction 
The effect of silicone oil on protein stability is an area that is still under investigation, and 
not well understood.  There have been several reports showing silicone oil has no effect 
on protein stability, and yet other studies suggest the silicone oil droplets can induce 
aggregation [33, 34].  It appears that interactions between protein and silicone oil may be 
dependent upon the protein molecule.  A study was performed to look at the effect of 
protein in the presence of silicone oil droplets (as an emulsified suspension) [35].  It was 
hypothesized that protein was coating the silicone oil droplets and could affect the zeta 
potential of these particles leading to increased or decreased stability of the suspension.  
There was quite a bit of indirect evidence that protein was actually coating the oil 
droplets including the change in oil droplet size and state of aggregation in the presence 
of protein.  Oil emulsions without protein were found to contain discrete droplets less 
than 10 µm in size.  After exposure to protein, droplets were highly aggregated with an 
average size of approximately 100 µm.  In addition, there was a loss of soluble protein 
for all formulations after exposure to silicone oil, with no increase in aggregate levels.  
The findings suggest that protein was coating the oil droplets. 
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The objective of this study was to investigate the effect of the presence of silicone oil on 
the physical stability of model proteins, and most importantly, to be able to distinguish 
between protein particles and silicone oil particles.  This study looked at the effect of two 
proteins, bovine serum albumin (BSA) and ovalbumin, when exposed to silicone oil 
particles under stressed conditions.  BSA is reported to have a higher surface 
hydrophobicity than ovalbumin, but studies show that the binding of hydrophobic probes 
is a combination of hydrophobic binding sites and nearby charged residues [36].  The 
goal was to detect any interaction between protein and the silicone oil particles, and 
characterize any resultant particles. 
 
4.2  Materials and Methods 
4.2.1  Materials 
Model proteins were used for this study, including Bovine Serum Albumin (Sigma 
#A4503) and Ovalbumin (Sigma (#A5503-1G). Both proteins were reconstituted in 1X 
phosphate buffered saline (PBS), pH 7.2 (Gibco 20012) at 10 mg/mL. 
 
Silicone oil (Dow Corning, 350 CST), 360 medical fluid grade was used throughout this 
study.  Oil suspensions were made in deionized water (1% vol/vol), emulsified before 
use. 
 
Samples were prepared in 1 mL glass vials (Schott part # 68000313).  The vials were 
washed with particle free water (MilliQ) and depyrogenated. Serum stoppers were used 
to seal vials as needed.  West (# 19560182-S2-F451 R-B2-40) 13 mm stoppers were used 
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after washing with particle-free water and autoclaving.  All the materials used in this 
study were used and stored under low particulate conditions in a laminar flow hood. 
 
Microscopic analysis was performed using a Nikon ME600 optical microscope equipped 
with a Spot digital camera and ImagePro image capture and analysis software.  Thermal 
analysis was performed using a MicroCal DSC system.  Analysis was performed at a 100 
ºC/hr scan rate, over a range of 20-110 ºC.  Samples were analyzed at 2.5 mg/mL.  SDS-
PAGE analysis was performed using NuPAGE polyacrylamide gels and a colloidal blue 
stain.  Both reduced and non-reduced conditions were tested.  Gels were de-stained and 
analyzed using a Bio-Rad GS-800 densitometer.  UV spectroscopy was performed using 
a Nanodrop system.  A Brightwell MFI DPA4200 was used for any flow imaging 
analysis. 
 
4.2.2  Silicone Oil Preparation 
To create conditions that are pharmaceutically relevant, the type of silicone oil that a 
sample would encounter (from a prefilled syringe coating for example) was introduced.  
In order to dispense and handle the oil, an emulsion was created.  The emulsion was 
found to be stable 30 minutes after preparation, as determined by flow image analysis.  
The silicone oil emulsion was prepared as follows for all studies performed: 
 
A 1% solution of silicone oil was made in 0.2 um filtered 1X PBS buffer, pH 7.2, in a 
cleaned plastic conical tube.  The sample was vigorously shaken (complete inversions) 
for 10 sec.  The suspension was then subjected to 10 min sonication in a sonic bath.  This 
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was followed by an additional 10 sec of vigorous shaking.  The sample was then used 
immediately when possible, and within 30 minutes of preparation if needed. 
 
4.2.3  Protein Sample Preparation 
Care was taken during the preparation of all samples to avoid introduction of foreign 
particulate matter.  All samples were prepared and handled in a laminar flow cabinet and 
all materials were rinsed with particle free water as necessary to reduce foreign 
contamination. 
 
Samples were heated at 85 ºC for 15 min with agitation to induce aggregation for visual 
evaluation. 
 
A 1% silicone oil emulsion was prepared and added to the protein solutions at a 1:1 
volume ratio, resulting in an oil concentration of 0.5% in the protein samples. 
 
Sample formulations were prepared as shown in Table 4.1.  An appropriate volume of 
PBS was added to the protein solutions that did not contain silicone oil as a control. 
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Table 4.1.  Formulation details for test samples. 
Vial Code 
Protein  
Protein conc 
(mg/mL) 
1% silicone oil 
suspension added # vials 
B1 BSA 10 0 (PBS dilution) 1 
B2 BSA 10 1:1 with protein 1 
O1 Ovalbumin 10 0 (PBS dilution) 1 
O2 Ovalbumin 10 1:1 with protein 1 
S1 None 0 1:1 dilution w/buffer 1 
 
4.2.4  SDS-Page 
SDS-PAGE was performed on the samples, using the components listed in Table 4.2. 
 
Table 4.2.  Components used in SDS-Page analysis. 
Item Vendor Cat # Lot 
Gels- NuPAGE 4-12% Bis/tris 1mmX12 wells Invitrogen NP0322BOX 9061276 
Sample buffer- NuPAGE LDS sample buffer 
4X Invitrogen NP0007 555099 
Running Buffer/NuPAGE MES SDS 20X Invitrogen NP0002 572203 
Novex Stainer A, colloidal blue kit Invitrogen 46-7015 453724 
Novex Stainer B, colloidal blue kit Invitrogen 46-7016 453725 
 
4.2.5  Optical Microscopy 
Optical microscopy was performed on the samples to determine the morphology and 
abundance of particles in the samples.  The presence of silicone oil droplets was easily 
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identified based on shape and optical properties.  Samples were examined neat, with no 
coverslip. 
 
4.2.6  Fluorescence Microscopy 
Fluorescence microscopy was employed to aid in the visualization of protein aggregates 
when formed in the presence of silicone oil droplets.  A variety of fluorescent dyes were 
evaluated including ThioflavinT, ANS, congo red, and nile red.  Nile red was found to 
provide the best imaging properties with longer time before quenching.  Nile red was 
used for all fluorescence studies described.  A 1 mM solution of nile red in ethanol was 
used throughout.  It was determined that nile red had very minimal affinity for the 
silicone oil droplets making it a very useful dye for determining if protein was present 
when silicone oil was also present.  
 
4.3  Results 
4.3.1  Silicone Oil Emulsion 
A sample of the silicone oil emulsion was prepared and monitored over time.    The 
emulsion was prepared and evaluated at 30 min. and after 4 days sitting at 2-8ºC.  The 
goal was to allow the emulsion to sit for a prolonged period of time to allow for 
coalescence/stability and then try to regenerate the particles by introducing energy into 
the system.  The turbidity of the sample was much less than at T0 after 4 days, so the 
sample was re-sonicated and shaken to recreate the emulsion.  This sample was evaluated 
by dynamic imaging and found to contain a much finer dispersion of particles, very 
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different from the original emulsion.  Fresh emulsion preparations were used in this 
study, based on this information. 
 
Particle count results for the emulsion samples are shown in Table 4.3.  The particle 
counts for a water blank were included, demonstrating the minimal contribution from the 
background.  Corresponding images for these samples are shown in Figures 4.1 to 4.3.  
The images indicate that the re-emulsified sample contained much finer particles.  There 
were a great deal more particles generated, with many touching in the images.  Crowded 
images like this can lead to erroneous results, where the analysis software sees the 
agglomerate of particles as a single unit of larger size.  This was reflected in the larger 
mean size (ECD) value reported for this sample. 
 
It was determined that the prepared emulsion should be used within 30 min. after 
preparation.  This time frame ensured there was a sufficient amount of particles 
remaining with a desired particle size distribution. 
 
Table 4.3.  Particle count results for the silicone oil emulsion at initial and 30 min after 
preparation.  In addition, the results for a water blank and for the re-emulsified sample, 
after 4 days are included. 
Sample 
Mean ECD 
(um)
Total conc 
(p/mL) ≥1 to <2 ≥2 to <5 ≥5 to <8 ≥8 to <10 ≥10 to <25 ≥25 to <50 ≥50 to <100
water blank 1.8 77 67 7 0 2 2 0 0
1% emulsion in PBS, T0 3.5 13143857 6157661 4604569 1286710 414143 598511 81071 1192
1% emulsion in PBS, 
T30min 3.3 7895587 3791819 2745598 723397 259252 355908 19432 181
1% emulsion, T4 days, 
resonicated 7.7 17535293 5822272 4214073 2135652 1015940 3256868 977440 112546
Particles/mL, size range in µm
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Figure 4.1.  Images from the flow imaging system showing the particles detected at each 
size range for the emulsion at the initial time point. 
 
Particles 2 to 5 µm (equivalent circular diameter)
Particles5 to 8 µm (equivalent circular diameter)
Particles 8 to 10 µm (equivalent circular diameter)
Particles10 to 25 µm (equivalent circular diameter)
Particles 25 to 50 µm (equivalent circular diameter)
Particles 50 to 100 µm (equivalent circular diameter)
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Figure 4.2.  Images from the flow imaging system showing the particles detected at each 
size range for the emulsion at the 30 min time point. 
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Figure 4.3.  Images from the flow imaging system showing the particles detected at each 
size range for the re-emulsified sample. 
 
Particles 2 to 5 µm (equivalent circular diameter)
Particles5 to 8 µm (equivalent circular diameter)
Particles 8 to 10 µm (equivalent circular diameter)
Particles10 to 25 µm (equivalent circular diameter)
Particles 25 to 50 µm (equivalent circular diameter)
Particles 50 to 100 µm (equivalent circular diameter)
 
 
4.3.2  Protein Analysis in the Presence of Silicone Oil 
4.3.2.1  DSC 
The protein samples were analyzed by DSC to determine if there was any change in the 
melting temperature (Tm) for the samples in the presence of silicone oil particles.  The 
DSC thermograms are shown in Figure 4.4.  A table showing the Tm values for each 
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sample is shown in Table 4.4.  The neat silicone oil emulsion was also analyzed.  The 
results show no effect of silicone oil on Tm values for any of the samples.  Sample details 
are listed in Table 4.1. 
 
Figure 4.4.  DSC thermograms for all samples tested. 
 
Solid red:  (O1) Ovalbumin with no silicone oil 
Dashed red: (O2) Ovalbumin with silicone oil 
Solid blue:  (B1) BSA with no silicone oil 
Dashed blue:  (B2) BSA with silicone oil 
Dashed black:  silicone oil suspension 
Yellow:  blank baselines 
 
Table 4.4.  Tm values for all samples tested, including the neat silicone oil emulsion.  
Sample  Tm 
B1 BSA 63.3 
BB2 BSA 63.3 
O1 albumin 78.4 
O2 albumin 78.4 
96 
 
 
4.3.2.2  SDS-PAGE 
The albumin samples were heated at 85ºC for 15 min with agitation, to induce 
aggregation.  Samples were evaluated in the presence and absence of silicone oil particles 
and analyzed by reduced and non-reduced SDS-PAGE.  Table 4.5 lists the SDS-PAGE 
results for the samples.  The % High Molecular Weight Species (%HMWS) and % parent 
compound remaining are listed.  Figures 4.5 and 4.6 show images of the reduced and 
non-reduced gels.  The first two lanes contain molecular weight markers (Invitrogen cat 
#LC5677, 12 band marker set), with the molecular weights listed in the image.  A 
silicone oil sample was analyzed as a blank (lane 3). 
 
SDS-PAGE results indicate that there was a significant amount of irreversible 
aggregation with heating both albumin samples.  The larger aggregates were dissociated 
after adding a reducing agent, suggesting reduction of disulfide linkages.  Most 
importantly, no significant effect of having silicone oil present was observed. 
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Table 4.5.  SDS-PAGE results for the samples, showing the percent calculated for the 
%HMWS and parent species, determined by densitometry of the colloidal blue stained 
gels. 
 
Non Reduced     
Sample ID %HMWS %Parent 
B1 (BSA) 39 59 
B2 (BSA/Oil) 38 59 
O1 (OA) 13 78 
O2 (OA/Oil) 11 78 
B1 (BSA) Heated >90 <10 
B2 (BSA/Oil) Heated >90 <10 
O1 (OA) Heated 57 39 
O2 (OA/Oil) Heated 69 28 
      
Reduced     
Sample ID %HMWS %Parent 
B1 (BSA) 26 74 
B2 (BSA/Oil) 25 75 
O1 (OA) 11 86 
O2 (OA/Oil) 12 82 
B1 (BSA) Heated 34 64 
B2 (BSA/Oil) Heated 35 61 
O1 (OA) Heated 20 64 
O2 (OA/Oil) Heated 21 63 
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Figure 4.5.  Image of the non-reduced gel.  The lanes are labeled with the sample name.  
Non-heated samples are in lanes 4-7, lanes 9-12 on the right-hand side of the gel are the 
heated samples, in the same order. 
 
 
Figure 4.6.  Image of the reduced gel, showing the dissociation of aggregates created with 
heating.  The lanes are labeled with the sample name.  Non-heated samples are in lanes 4-
7, lanes 9-12 on the right-hand side of the gel are the heated samples, in the same order. 
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4.3.2.3  Optical Microscopy 
Optical microscopy was also performed on the samples to determine the physical state of 
the samples right before DSC and SDS-PAGE analysis.  No aggregates were observed, 
and silicone oil droplets were easily detected in samples containing the emulsified oil. 
A photomicrograph of the silicone oil emulsion is shown in Figure 4.7.  The oil particles 
had a broad size distribution.  The BSA and Ovalbumin samples, after preparation and 
before adding silicone oil (no heating), were evaluated with no particles observed (no 
images provided).  
 
Figure 4.7.  Silicone oil emulsion sample, 200X total magnification. 
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All samples were again imaged after DSC and SDS-PAGE analysis.  The proteins had 
time to sit in the presence of the oil particles.  Figure 4.8 shows the silicone oil 
suspension after sitting.  Fine oil droplets are still present, but the larger droplets are no 
longer observed.  The BSA and Ovalbumin samples (no oil added), after sitting, had no 
observable particles (no image provided).  The BSA plus silicone oil sample, after sitting, 
still contained the oil droplets but no protein like particles were observed (Figure 4.10).  
The Ovalbumin plus silicone oil sample, after sitting, still contained oil droplets and 
some small protein like particles.  There appeared to be some association of the protein 
with the oil droplets, a fine coating was seen in some microscope fields (Figure 4.13). 
 
Next, heat was applied to the samples and all were examined again.  The silicone oil 
suspension had the same appearance as before heating (Figure 4.9).  The BSA sample, 
after heating, contained many sheet like and fibrous aggregates, as shown in Figure 4.11.  
The BSA sample with silicone oil after heating, however, did not contain the fibrous or 
sheet like particles.  Rather, a large number of spherical particles, resembling the silicone 
oil droplets were observed (Figure 4.12). 
 
The Ovalbumin sample, after heating, was also examined.  The sample contained a great 
deal of sheet like and fibrous aggregates as shown in Figure 4.14.  The Ovalbumin and 
silicone oil sample, after heating, showed a significant change in particle morphology.  
Some spherical particles resembling silicone oil droplets were seen, and many small, 
more equant aggregates were observed (Figure 4.15).  These particles were examined 
under higher magnification, and it appeared that the protein had aggregated and was 
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intimately associated with silicone oil droplets.  Figures 4.16 and 4.17 show 
representative aggregates, demonstrating the association with the oil droplets.  Under 
high magnification, the association between protein and silicone oil droplets was clearly 
seen.  These results indicate the presence of silicone oil can affect the morphology of 
protein aggregates and must be considered when present during particle characterization 
studies. 
 
 
 
Figure 4.8.  The silicone oil suspension 
after incubation.  Fine oil droplets were 
still present, but the larger droplets were 
no longer observed. 100X total 
magnification. 
 
 
Figure 4.9.  The silicone oil suspension 
sample, after heating.  The sample had 
the same appearance as before heating 
with an abundance of small droplets 
observed.  100X total magnification. 
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Figure 4.10.  The BSA plus silicone oil 
sample, after incubation, still contained 
the oil droplets, but no protein like 
particles were seen.  100X total 
magnification. 
 
 
Figure 4.11.  The BSA sample, after 
heating, contained many sheet like and 
fibrous aggregates.  A representative 
particle is shown.  100X total 
magnification. 
 
 
Figure 4.12.  The BSA sample with silicone oil after heating.  Fibrous and sheet like 
aggregates were not seen.  Spherical particles resembling the silicone oil droplets were 
observed.  Total magnification 100X. 
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Figure 4.13.  Ovalbumin plus silicone oil 
sample, after incubation, still contained 
oil droplets and some small protein like 
particles.  There appeared to be some 
association of the protein with the oil 
droplets.  100X total magnification. 
 
 
Figure 4.14.  The Ovalbumin sample, 
after heating, contained a great deal of 
sheet like and fibrous aggregates as 
shown.  100X total magnification. 
 
 
Figure 4.15.  The Ovalbumin and silicone oil sample, after heating, showed a significant 
change in particle morphology.  Some spherical particles resembling silicone oil droplets 
were seen, as well as many equant aggregates.  100X total magnification. 
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Figure 4.16. Representative aggregates found in the ovalbumin plus silicone oil samples 
after heating.  The morphology of the aggregate was more equant and was associated 
with silicone oil droplets.  200X total magnification. 
 
 
Figure 4.17. Representative aggregates found in the ovalbumin plus silicone oil sample 
after heating.  This high magnification photo shows the protein aggregate associated with 
the silicone oil droplets.  The spherical morphology and optical properties of the oil 
droplets were easily identified.  400X total magnification. 
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4.3.2.4  Fluorescence Microscopy 
Based on the change in aggregate morphology observed with the presence of silicone oil, 
an additional study was conducted to further characterize these particles.  Dyes have been 
used to enhance the contrast of protein particles, as discussed earlier in this report.  
Fluorescence microscopy was employed to aid in visualizing the protein aggregates 
formed in the presence of silicone oil droplets.  Nile red dye was added to the various 
protein solutions immediately before viewing under the microscope (structure shown 
below). 
 
 
Nile Red 
C20H18N2O2 
MW:  318.369 g/mol 
Structure 4.1 
 
It was observed that the silicone oil emulsion sample provided minimal fluorescence 
when mixed with the dye (Figure 4.18), suggesting that the dye does not interact with the 
oil.  This confirmed that a low background would be achieved when analyzing samples.  
In addition, dye was added to a solution containing ovalbumin and silicone oil droplets, 
and again there was very little dye associated with the droplets (photo not shown).  Next, 
samples of ovalbumin and BSA, stressed through heating (as described previously), were 
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mixed with nile red and observed by microscopy (no oil added).  Protein aggregates were 
seen in all samples, as shown in Figures 4.19 and 4.22.  The aggregates were large and 
primarily sheet like and fibrous in morphology. 
 
Next, the protein samples were heated in the presence of silicone oil and the nile red dye 
added to the samples.  The protein aggregate morphologies were altered in the presence 
of the oil.  Aggregates were smaller and more equant in shape.  Figures 4.20-4.21 and 
4.23-4.24 show representative aggregates observed with silicone oil present. 
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Figure 4.18.  Silicone oil emulsion sample and nile red dye.  Very little fluorescence 
intensity was observed.  100X total magnification. 
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Figure 4.19.  BSA, heated, mixed with 
nile red dye.  Large sheet like aggregates 
were formed.  A representative 
aggregate is shown, 100X total 
magnification. 
 
Figure 4.20 .  BSA plus silicone oil 
sample, after heating. Much smaller and 
more equant particles as well as shorter 
fibers seen.  200X total magnification. 
 
 
Figure 4.21.  BSA plus silicone oil sample, after heating. 100X total magnification. 
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Figure 4.22.  Ovalbumin, heated, mixed 
with nile red dye.  Sheet like aggregates 
were observed, as shown.  200X total 
magnification. 
 
Figure 4.23.  Ovalbumin plus silicone oil 
sample, after heating. 400X total 
magnification. 
 
 
 
Figure 4.24.  Ovalbumin plus silicone oil sample, after heating. 400X total magnification. 
 
 
 
4.4  Discussion  
After a period of incubation, the silicone oil emulsion sample had a decrease in larger 
particles.  However, in the presence of protein, the larger oil droplets are still observed, 
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suggesting that they are being stabilized by the protein in solution.  In the case of 
ovalbumin, the association of protein and silicone oil was readily observed by optical 
microscopy.  DSC suggested that silicone oil does not affect the Tm of the proteins 
studied.  It has been demonstrated previously, that silicone oil at 0.5%, had slight to no 
effect on the thermal unfolding temperature (Tm) of model proteins including BSA [37]. 
 
An objective of this study was to determine what techniques could be used to characterize 
particles in protein solutions, when silicone oil droplets are present.  Optical microscopy 
can provide a quick and easy method for determining the morphology and abundance of 
particles in solution (with a lower limit of resolution around 1-2 µm).  In addition, the 
study suggested that in the presence of silicone oil, protein aggregate morphology can be 
affected.  If the protein associates with the silicone oil droplets, a smaller and more 
equant aggregate may form.  This has implications in particle size and count analysis, 
especially if samples are being analyzed during drug product development and later 
introduced to a siliconized surface such as a pre-filled syringe.  Also, protein has been 
observed coating silicone oil droplets (Figure 4.24).  In this situation, the particles could 
not be differentiated from silicone oil droplets by techniques such as flow imaging.  The 
ability to differentiate silicone oil particles from protein was a goal of this work.  
Although a visible dye can provide some contrast between a protein coated oil droplet 
and non-coated droplet, a fluorescent dye can greatly enhance this contrast.  The 
fluorescent dye associated with the protein where minimal to no interaction took place 
with the oil.  Particles were viewed using a fluorescent microscope.  Image analysis can 
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be employed for further analysis including information on morphology and how protein 
might be associated with the oil. 
 
4.5  Summary 
The results of this study suggest that silicone oil droplets can interact with protein, 
especially when the protein solution is undergoing a stress (thermal, mechanical, etc.).  
Moreover, the ensuing particles can be quite different in morphology from the aggregates 
that would form without oil droplets present.  It is assumed that as the protein unfolds and 
aggregates, hydrophobic areas become exposed.  This increased hydrophobicity 
(exposure of hydrophobic protein groups) can lead to attraction of other hydrophobic 
surfaces such as the pendant methyl groups off the silicone backbone in silicone oil [38].  
Silicone oil droplets are abundant in prefilled syringes and found in certain vial stoppers 
[39].  When assessing the stability of protein solutions upon stress conditions such as heat 
or agitation, the presence of oil droplets could interfere with accurate particle 
characterization assays.  It has been suggested that dynamic flow imaging (such as the 
Brightwell MFI) may be used to electronically ‘filter’ equant particles during analysis.  
Our data indicate caution should be used because these equant particles may actually be 
complexes of silicone oil droplets and aggregated protein, resulting in gross 
undercounting of protein particles.  Care must be taken to assess the composition of the 
particles detected, especially in systems such as prefilled syringe. This dye-based assay, 
utilizing Nile red, provides a tool to differentiate silicon oil droplets from both protein-
coated silicone oil droplets and protein aggregates. 
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Chapter 5.  Summary and Future Work 
 
The studies described in this dissertation allow for determination of particle counts and 
characterization of particles found in protein drug products using a minimal amount of 
sample volume.  All methods were developed with the goal of providing the most 
information on protein aggregates, using the least amount of sample.  In addition, it has 
been demonstrated that silicone oil particles do not appear to induce protein aggregation 
for the proteins studied, but silicon oil did interact with proteins during aggregation by 
incorporating into the aggregates, as was observed by optical microscopy. Fluorescence 
microscopy studies suggest that protein can also coat the silicone oil droplets.  This can 
affect the physical properties of the protein aggregate, including morphology, creating a 
more uniform, equant aggregate, which may be of concern with respect to 
immunogenicity.  This interaction also makes differentiation between protein/oil droplets 
and neat silicone oil droplets difficult, highlighting the need for new methods. 
 
Future work will include further optimization of the low volume light obscuration 
method, including additional validation studies to determine the effect of viscosity when 
analyzing higher concentration protein samples (> 100 mg/mL).  This method can 
provide results that meet the USP criteria, while minimizing the amount of sample 
needed for analysis.  By performing these additional validation/robustness studies, the 
method can be transferred to routine analysis labs (such as a QC lab) for stability and 
release testing. 
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Additional work will also continue in the development of imaging techniques using 
visible and fluorescent dyes.  These techniques are ideally suited for the characterization 
of larger (visible) protein particles.  The use of a dye to enhance the visual contrast of 
protein particles and a filter membrane could be used to develop orthogonal techniques to 
visual inspection testing.  With the use of automated image analysis, determination of the 
amount of particles as well as morphological and compositional information could be 
obtained.  Enhancing the visualization of protein particles could be very advantageous 
when performing formulation development studies, where visual inspection is performed 
on vials with small volumes of drug product.  The ability to detect translucent fibrous 
protein particles under those conditions is limited.  One study that is ongoing, is the use 
of fluorescent dyes to enhance visualization of protein in the presence of silicone oil 
particles.  Studies to understand the coating of a protein on a silicone oil droplet is of 
great interest. 
 
It is well accepted that the amount and size of particles in parenteral products is a critical 
quality attribute.  In addition, it is highly recommended that the composition of these 
particles be understood to fully understand the quality of the product.  The techniques 
introduced here can be used to aid in characterization of particulate matter, using minimal 
amounts of sample. 
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